Serous endometrial intraepithelial carcinoma (SEIC): Current clinical practice in The Netherlands

Ciska Slaager, Ward Hofhuis, Klaas Hoogduin, Patricia Ewing-Graham, Heleen van Beekhuizen

European Journal of Obstetrics & Gynecology and Reproductive Biology 265 (2021) 25–29

Contents lists available at ScienceDirect
European Journal of Obstetrics & Gynecology and Reproductive Biology
journal homepage: www.elsevier.com/locate/euro

FULL LENGTH ARTICLE

Full length article

Serous endometrial intraepithelial carcinoma (SEIC): Current clinical practice in The Netherlands

Ciska Slaager, Ward Hofhuis, Klaas Hoogduin, Patricia Ewing-Graham, Heleen van Beekhuizen

In the absence of demonstrable invasion, the intraepithelial lesions can shed malignant cells and metastasize to extrauterine sites. There have been several hypotheses as to the mechanism of dissemination of malignancy in SEIC. Current evidence supports the idea that the extrauterine tumor cells are not independent but are metastatic from the (superficial) uterine tumor. SEIC is a histopathological diagnosis; the cells of SEIC are identical to serous type endometrial carcinoma. SEIC is considered to be potentially metastatic, however clear and robust data on prognosis are lacking, potentially leading to variability in clinical management. The aim is to establish the opinion of gynecologists on the optimal management of patients with SEIC.

Methods: An online questionnaire with 15 multiple choice questions was sent to all gynecologists with expertise in gynecological oncology in 19 expert centers in The Netherlands.

Results: A total of 24 gynecologists participated. The majority of respondents (n = 18/24, 75%) do not consult a guideline regarding the treatment of SEIC. In current practice, 14 of the 24 respondents perform surgical staging in women with SEIC (58.3%) while seven choose hysterectomy with bilateral salpingo-oophorectomy (29.2%), and three (12.5%) have no firm preference. Eleven of the 14 respondents who perform a surgical staging procedure believe that this is certainly the optimal treatment. The majority of respondents have no firm opinion on whether lymph node sampling or lymph node dissection is preferable during surgical staging (n = 15/23, 65.2%). Most respondents do not give adjuvant therapy (n = 15/24, 62.5%), 25.0% recommend brachytherapy (n = 6/24). Follow-up is for 5 years in almost all cases (n = 23/24). Conclusion: There is no consensus on the optimal surgical treatment and the use of adjuvant therapy for patients with SEIC. Our research team is therefore conducting a nationwide cohort study in which treatment modality, morbidity, mortality and survival will be evaluated.

© 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Introduction: Serous endometrial intraepithelial carcinoma (SEIC) is a rare diagnosis, defined as an intraepithelial lesion with cells identical to serous type endometrial carcinoma. SEIC is considered to be potentially metastatic, however clear and robust data on prognosis are lacking, potentially leading to variability in clinical management. The aim is to establish the opinion of gynecologists on the optimal management of patients with SEIC.

Methods: An online questionnaire with 15 multiple choice questions was sent to all gynecologists with expertise in gynecological oncology in 19 expert centers in The Netherlands.

Results: A total of 24 gynecologists participated. The majority of respondents (n = 18/24, 75%) do not consult a guideline regarding the treatment of SEIC. In current practice, 14 of the 24 respondents perform surgical staging in women with SEIC (58.3%) while seven choose hysterectomy with bilateral salpingo-oophorectomy (29.2%), and three (12.5%) have no firm preference. Eleven of the 14 respondents who perform a surgical staging procedure believe that this is certainly the optimal treatment. The majority of respondents have no firm opinion on whether lymph node sampling or lymph node dissection is preferable during surgical staging (n = 15/23, 65.2%). Most respondents do not give adjuvant therapy (n = 15/24, 62.5%), 25.0% recommend brachytherapy (n = 6/24). Follow-up is for 5 years in almost all cases (n = 23/24). Conclusion: There is no consensus on the optimal surgical treatment and the use of adjuvant therapy for patients with SEIC. Our research team is therefore conducting a nationwide cohort study in which treatment modality, morbidity, mortality and survival will be evaluated.

© 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
carcinoma’, ‘superficial serous carcinoma’, ‘minimal uterine serous carcinoma’ and ‘serous endometrial intraepithelial neoplasia’. It has been suggested that the term SEIC should be used, to standardize international nomenclature.[8]

Although it is generally accepted that SEIC is a non-invasive lesion which can present with disseminated disease, there are in fact few data on the prognosis of patients with SEIC. The WHO recommends surgical staging of disease (hysterectomy, bilateral salpingo-oophorectomy, omentectomy, lymph node sampling, peritoneal biopsies and peritoneal washings).[2,7] However, in patients with SEIC there is no international guideline, nor is there evidence – besides the statement of the World Health Organization – on the optimal surgical approach. In daily practice, clinicians may be uncertain whether to perform a complete staging procedure or not. In the absence of guidelines, clinical practice may vary from hysteroscopic resection to complete surgical staging. According to a cohort study by Pathiraja, optimum surgical staging with appropriate adjuvant treatment should at least be considered when treating these patients.[1]

This study describes current clinical practice in The Netherlands and the attitude of Dutch gynecologists towards the treatment of SEIC.

Methods

Population

An open, online questionnaire was sent to all 19 Dutch centers for gynecological oncology. A mailing list of gynecologists trained in gynecological oncology was created by contacting the 19 medical centers (of which seven are academic medical centers) who organize and perform the treatment of uterine carcinoma. All gynecologists from these hospitals who are trained in gynecological oncology and have expertise in endometrial malignancy were contacted by e-mail or by telephone. All gynecologists gave their consent for participation prior to the link for the online survey being sent.

Questionnaire

The questionnaire was developed and then checked using the ‘Checklist for Reporting Results of Internet E-Surveys (CHERRIES)’[16]. The questionnaire was conducted using Google Forms (Google, Menlo Park, USA, 1998. https://www.google.com/forms/about/). The questions were composed and formulated by the main researcher (CS) who is a gynecology resident and further reviewed and adjusted by one gynecologist with expertise in gynecological oncology (WH) and one gynecological oncologist (HB). The link to the questionnaire was first sent in March 2020. Two reminders were sent after 4 and 6 weeks. The link was closed after 10 weeks. The participating gynecologists could only respond once. Since this study population consists exclusively of physicians, ethical approval was not necessary.

The questionnaire consisted of 15 questions, all multiple choice. After each question, there was the possibility to add additional information or elaborate more on the topic. Additionally, three fictitious cases were presented, each with a question attached. All 18 items were designed to evaluate current clinical practice and current attitudes towards the management of patients with SEIC. The questions covered the number of patients that were treated in the hospitals, which diagnostic tests were used, whether there were local guidelines used for the initial and/or adjuvant treatment, whether the gynecologist always performed surgical staging and whether there were local guidelines regarding the duration of follow-up. Regarding the therapeutic options, several options were provided: no treatment (‘watchful waiting’), hysteroscopic polypectomy, hysterectomy with bilateral salpingo-oophorectomy or a surgical staging procedure. Surgical staging includes – according to international guidelines – aspiration of peritoneal washings, inspection of all visceral organs, hysterectomy and bilateral oophorectomy, infracolic omentectomy, biopsy of suspect lesions and suspect adhesions, biopsy of the peritoneum (recto-uterine pouch; urinary bladder; pelvic peritoneum; para-coolic gutters; diaphragm) and lymph node sampling (minimum of 10 lymph nodes from the para-aortic, paracaval and pelvic regions).

Analysis

The outcomes of the questionnaire were collected and analyzed with SPSS v.25, using descriptive statistical methods.

Results

A total of 24 gynecologists participated, from 16 different medical centers (appendix 1)(16 out of 19 medical centers were included, with a response rate of 84.2%). Of all participants 18 (75.0%) were gynecological oncologists, four (16.7%) were gynecologists with expertise in gynecological oncology and two (8.3%) were fellows. With respect to the number of patients with SEIC treated in the previous five years: 13 out of the 24 respondents (54.2%) estimated that they had treated 5–10 patients. Of all respondents (n = 24) 95.8% (n = 23/24) claimed to have treated at least one patient in the previous five years (table 1). The majority of respondents do not use – or do not have – a clinical guideline in their medical center (n = 18/24, 75.0%). Six (25.0%) do consult a clinical guideline when treating patients with SEIC.

Regarding the diagnostic tests used for SEIC: twenty two respondents (91.7%, n = 22/24) use CA-125 as a biomarker. A computed tomography (CT) scan is often used for imaging of the thoracic and abdominal organs: twenty respondents (83.3%, n = 20/24) perform a CT scan of both the abdomen and thorax, two (2/24, 8.3%) use CT imaging only for the abdomen and two do not use computed tomography at all (2/24, 8.3%).

Current clinical treatment varies from therapeutic hysterectomy to complete surgical staging (table 2a). The majority of respondents perform complete surgical staging (n = 14/24, 58.3%) whereas seven choose for hysterectomy with bilateral salpingooophorectomy (n = 7/24, 29.2%). When the diagnosis SEIC is an incidental finding after polypectomy or hysterectomy performed for another indication, 62.5% of respondents (n = 15/24) go on to perform surgical staging, while 33.3% (n = 8/24) prefer to opt for follow-up alone. One respondent would perform a computed tomography scan and then discuss with the patient whether surgical staging or chemotherapy with radiotherapy is preferred (n = 1/24, 4.2%)(table 2b).

When surgical staging is performed, this always includes hysterectomy with bilateral salpingo-oophorectomy and biopsy of the omentum. Biopsies of the peritoneum and diaphragm are carried out by 73.9% of respondents (n = 17/23). Sampling of pelvic and para-aortic lymph nodes is included in the staging procedure by 21/23 respondents (87.5%); while two opt for lymph node dissection (n = 2/23, 8.7%). Cytological examination of peritoneal washings is included by 78.3% (n = 18/23)(table 3).

Three respondents provided extra details regarding their clinical practice: (1) “the treatment depends on whether the pathological result was extracted from a polyp or if it was obtained through aspiration of the endometrial lining: in the first scenario resection of the polyp is performed, in the second scenario a hysterectomy with oophorectomy is performed”; (2)“when the pathological result is obtained from aspiration of the endometrium a hysterectomy is performed, since it is then often described as a serous
endometrial carcinoma rather than SEIC\(^{c}\); (3)"surgical staging is the first choice of treatment, however without examination of peri-

toneal washings". When gynecologists were asked for their opinion on the optimal treatment for patients with SEIC, complete staging was considered to be the optimal treatment by 50.0% (12/24), whereas 37.5% (n = 9/24) consider hysterectomy with salpingo-

oophorectomy to be the optimal treatment. Three respondents (n = 3/24, 12.5%) are unsure when asked for their opinion on optimal treat-

ment for patients with SEIC (table 4a). Of those 14 gynecologists who choose surgical staging as their current practice, 11 consider this to be the optimal treatment (n = 11/14, 78.6%), two answered that hysterectomy and bilateral salpingo-

Table 1

| Number of estimated patients treated with SEIC per participant in the last five years. |
|-----------------|-----------------|
| Number of patients | n | % |
| 0                | 0   | 0  |
| 1–5              | 7   | 29.2 |
| 6–10             | 13  | 54.2 |
| 11–15            | 1   | 4.2 |
| 16–20            | 0   | 0  |
| >20              | 2   | 8.3 |
| 'I don’t know’   | 1   | 4.2 |

Table 2a

| Current treatment – SEIC suspected after biopsy or polypectomy. |
|-----------------|-----------------|
| Type of treatment | N   | % |
| Hysterectomy + bilateral salpingo-oophorectomy | 7   | 29.2 |
| Surgical staging | 14  | 58.3 |
| Other: polypectomy if SEIC is limited to an uterine polyp | 2   | 8.3 |
| 'I don’t know’   | 1   | 4.2 |

Table 2b

| Current treatment – when SEIC was a coincidental finding after hysterectomy. |
|-----------------|-----------------|
| Type of treatment | N   | % |
| Surgical staging | 15  | 62.5 |
| Follow-up ('watchful waiting') | 2   | 33.3 |
| Other: depending on imaging (computed tomography) | 1   | 4.2 |

Table 3

| Components of the surgical procedure during surgical staging | Number of participants (n)* | % |
|---------------------------------------------------------------|-----------------------------|---|
| Hysterectomy                                                 | 23                          | 100|
| Bilateral salpingo-oophorectomy                               | 23                          | 100|
| Lymph node sampling                                          | 18                          | 78.3|
| Lymphadenectomy                                              | 2                           | 8.7 |
| Biopsy of the omentum                                        | 23                          | 100|
| Biopsy of the peritoneum                                     | 17                          | 73.9|
| Biopsy of the diaphragm                                      | 17                          | 73.9|
| Cytological examination from peritoneal washings             | 18                          | 78.3|

Table 4

| Opinion on the optimal treatment of SEIC. |
|------------------------------------------|
| Type of treatment | Current treatment | Preferred treatment | Difference |
|-----------------|-----------------|-----------------|------------|
| Hysterectomy + BSO | 7               | 9               | 2          |
| Surgical staging | 14              | 12              | 2          |
| Other           | 2               | 0               | -2         |
| 'I don’t know’   | 1               | 3               | +2         |

*BSO: bilateral salpingo-oophorectomy
National Comprehensive Cancer Network in the USA recommends surgical staging and adjuvant therapy for serous carcinoma FIGO 1A and includes no separate section for the management of patients with SEIC.\[20,21\] The main issue is that the evidence for lymph node sampling, in particular lymph node dissection, is limited. It is uncertain whether SEIC metastasizes to pelvic or paraaortic/paracaval lymph nodes. Our hypothesis is that superficial intraepithelial carcinoma may spread through the tubes into the peritoneal cavity. Whether lymph node sampling or dissection is indicated in the treatment of SEIC remains unclear. In conclusion, it is of great importance to evaluate the influence of the choice of therapeutic management on the (disease free) survival. Staging is a comprehensive surgical procedure with a risk of complications, whether with laparotomy or with minimally invasive techniques.\[22,23\] Therefore, it is important to understand the influence of staging on (disease free) survival of patients with SEIC, and to assess whether the benefits of staging outweigh the potential risks. The authors of this article are therefore conducting a nationwide cohort study of 50 patients with SEIC where treatment modality, morbidity, progression free survival and overall survival will be evaluated.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

The authors acknowledge all gynecologists participating in our national survey.

Author contribution

This manuscript was drafted by Ciska Slaager, supervised and advised by the other members of the SEIC research team (Ward Hofhuis, Heleen van Beekhuizen, Patricia Ewing-Graham and Klaas Hoogduin).

Funding

None.

No financial support was obtained for conducting this study.

Appendix. A

Table A1

Participating medical centers with number of participants.

| Medical center                                                       | City        | n |
|---------------------------------------------------------------------|-------------|---|
| Albert Schweizer ziekenhuis                                        | Dordrecht   | 1 |
| Amsterdam University Medical Center                                | Amsterdam   | 1 |
| Amphia Ziekenhuis                                                  | Breda       | 1 |
| Antoni van Leeuwenhoek Ziekenhuis                                  | Amsterdam   | 2 |
| Bravis Ziekenhuis                                                  | Bergen op Zoom | 1 |
| Erasmus Medisch Centrum                                            | Rotterdam   | 2 |
| Franciscus Gasthuis en Vlietland                                   | Rotterdam   | 1 |
| Groene Hart Ziekenhuis                                             | Gouda       | 1 |
| Isala Ziekenhuis                                                   | Zwolle      | 1 |
| Leiden Universitair Medisch Centrum                                | Leiden      | 2 |
| Medisch Spectrum Twente                                            | Enschede    | 1 |
| Radboud Universitair Medisch Centrum                               | Nijmegen    | 2 |
| Reineer de Graaf Gasthuis                                          | Delft       | 1 |
| Universitair Medisch Centrum Groningen                             | Groningen   | 6 |
| Universitair Medisch Centrum Utrecht                               | Utrecht     | 1 |
| **Total**                                                          | **24**      |   |

Table 5

Current adjuvant therapy.

| Type of adjuvant therapy | n   | %   |
|--------------------------|-----|-----|
| None                     | 15/24 | 62.5 |
| Brachytherapy             | 6/24 | 25.0 |
| External-beam radiotherapy | 1/24 | 4.2  |
| Chemotherapy              | 1/24 | 4.2  |
| 'I don't know'            | 1/24 | 4.2  |

References

[1] Pathiraja P, Dhar S, Haldar K. Serous endometrial intraepithelial carcinoma: a case series and literature review. Cancer Manag Res 2013;5:117–22.

[2] IARC. World Health Organization Classification of Tumours: female genital tumours. 5 ed2020.

[3] Yan Z, Hui P. Minimal uterine serous carcinoma with extrauterine tumor of identical morphology: an immunohistochemical study of 13 cases. Appl Immunohistochem Mol Morphol 2010;18:75–89.

[4] Furuya M, Sato T, Tanaka R, Yamamoto M, Yokota NR, Miyagi E. Metachronous serous endometrial intraepithelial carcinoma and serous peritoneal carcinoma: analysis of probable independent lesions. Diagn Pathol 2016;11:130.

[5] Kawano K, Ushijima K, Yokomine M, Fukui A, Ijichi M, Kamura T. A case of minimal uterine serous carcinoma with distant lymph node metastasis without peritoneal dissemination. J Gynecol Oncol 2011;22(1):53. https://doi.org/10.3802/jgo.2011.22.1.53

[6] Baergen RN, Warren CD, Isacson C, Ellenson LH. Early uterine serous carcinoma: clonal origin of extrauterine disease. Int J Gynecol Pathol 2001;20(3):214–5.

[7] Kurman RJ. WHO classification of tumours of female reproductive organs. Lyon International Agency for Research on Cancer (IARC), 2014.

[8] Rabban JT, Zaloudek CJ. Minimal uterine serous carcinoma: current concepts in diagnosis and prognosis. Pathology 2007;39:125–33.

[9] Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15(1):10–7.

[10] Tashiro H, Isacson C, Levine R, Kurman RJ, Cho KR, Hedrick L. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. An J Pathol 1997;150:177–85.

[11] Hui P, Kelly M, O'Malley DM, Tavassoli F, Schwartz PE. Minimal uterine serous carcinoma: a clinicopathological study of 40 cases. Mod Pathol 2005;18(1):75–82.

[12] Stomovitz BM, Burke TW, Elfen PJ, Ramondetta LM, Silva EG, Jhungran A, et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol 2003;91(3):463–5.

[13] Hendrickson M, Ross J, Elfen P, Martinez A, Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982;6(2):93–108.
14. Boruta DM, Gehrig PA, Fader AN, Olawaiye AB. Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review. Gynecol Oncol 2009;115(1):142–53.

15. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394–424.

16. Eysenbach G. Improving the quality of Web surveys: the Checklist for Reporting Results of Internet E-Surveys (CHERRIES). J Med Internet Res 2004;6(3):e34. https://doi.org/10.2196/jmir.6.3.e34.

17. Giuntoli RL, Gerardi MA, Yemelyanova AV, Ueda SM, Fleury AC, Diaz-Montes TP, et al. Stage I noninvasive and minimally invasive uterine serous carcinoma: comprehensive staging associated with improved survival. Int J Gynecol Cancer 2012;22(2):273–9.

18. Wheeler DT, Bell KA, Kurman RJ, Sherman ME. Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation. Am J Surg Pathol 2000;24(6):797–806.

19. Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 2021;31(1):12–38.

20. Koh W-J, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, et al. Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2018;16(2):170–99.

21. Uterine Neoplasms, Version 3.2021.

22. Walker JL, Piedmonte MR, Spirito NM, Eisenkop SM, Schlaerth JB, Mannel RS, et al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol 2009;27(32):5331–6.

23. Manchana T, Puangsricharoen P, Sirisabya N, Worasethsin P, Vasuratna A, Termrungruanglert W, et al. Comparison of Perioperative and Oncologic Outcomes with Laparotomy, and Laparoscopic or Robotic Surgery for Women with Endometrial Cancer. Asian Pac J Cancer Prev 2015;16(13):5483–8.